01Apr 2024
Aragen operationalizes first phase of its US$ 30 million Biologics manufacturing facility in India

Aragen operationalizes first phase of its US$ 30 million Biologics manufacturing facility in India

Aragen, a Contract Research, Development, and Manufacturing Organization (CRDMO), inaugurated the first phase of its biologics manufacturing facility in Bangalore, India, through its subsidiary Aragen Biologics Pvt Ltd. This US$30 million investment facility executed its maiden small-scale manufacturing project for a US-based organization, producing a novel anticancer monoclonal antibody (mAb). Manni Kantipudi, CEO of Aragen Life Sciences and Director of Aragen Biologics, expressed satisfaction with the facility's commissioning, highlighting plans for full-scale Gene-to-GMP solutions. The facility, with advanced bioreactors, supports process development, validation, and manufacturing of mAbs and therapeutic proteins, enhancing Aragen's bioproduction capabilities.

  • #family health

Like

Save

Share